Letairis Articles

US FDA lifts liver injury warning on Gilead PAH drug Letairis

7 March 2011

AstraZeneca ends Certriad development with Abbott; Gilead drops ambrisentan in IPF

23 December 2010

Antiviral franchise boosts Gilead's 4th-qtr income 43% to $802.2 million

27 January 2010

Gilead's ambrisentan improves 6MWD in PH patients

20 May 2009

Profit up 22% at Gilead on pipeline strength

27 April 2009

Astellas walks away from CV, after "white knight" Gilead stepped in with a $1.4B bid

23 March 2009

Astellas drops pursuit of CV Thera after "white knight" Gilead offers $1.4B

23 March 2009

Stock Commentary - New York week to Sept 8, 2008

15 September 2008

Expanded indication for Actelion's PAH drug

7 July 2008

Stock Commentary - New York week to Jan 28, 2008

4 February 2008

Stock Commentary - New York week to Oct 29, 2007

5 November 2007

FDA NME and BLA approvals fall to 7 for 1st half 2007, was 11 in same period 2006

30 July 2007

Stock Commentary - New York week to June 25, 2007

2 July 2007

Stock Commentary - New York week to June 18, 2007

25 June 2007

Gilead's Letairis gets FDA OK for WHO Class I/II pulmonary arterial hypertension

25 June 2007

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end